Revive Therapeutics updates on several psilocybin initiatives to be completed in 2022
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued a progress update on its psilocybin pharmaceutical programs ahead of the first clinical study on psilocybin for methamphetamine use disorder.
The company is evaluating the psychedelic substance as a potential treatment for methamphetamine use disorder in conjunction with the University of Wisconsin-Madison. The study will be conducted at the university and provide proprietary information to support future US Food and Drug Administration (FDA) clinical studies.
“Revive is building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders,” the Toronto-based company said in a statement.
READ: Revive Therapeutics expects to complete patient enrollment for Phase 3 Bucillamine in coronavirus trial in first quarter this year
“We are embarking on our first clinical study evaluating psilocybin in the treatment of methamphetamine use disorder and advancing the development of an oral psilocybin thin file strip and psilocybin microneedle patch, which will offer flexible therapeutic solutions of psilocybin for unmet medical needs,” it added.
Revive also provided updates on several other psilocybin initiatives. The firm is evaluating psilocybin as a potential treatment for stroke, also with the University of Wisconsin-Madison. The proposed Phase I/II clinical study protocol to evaluate the safety and feasibility of psilocybin for stroke is expected to be submitted to the IRB in February.
In addition, Revive has initiated the product development program under a feasibility agreement with LTS Lohmann Therapie-Systeme AG to develop and manufacture a proprietary psilocybin oral thin film strip for mental illness, substance abuse and neurological disorders. Research prototype development is underway to support IND-enabling studies with the expectation to conduct a clinical study in 4Q 2022, the company said.
As for its microneedle patch program, Revive noted that it has finalized the project plan and will initiate IND-enabling studies with the expectation to conduct a clinical study in 4Q 2022.
Revive is also developing a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform under its research collaboration with North Carolina State University. The company expects to complete a research-grade batch of psilocybin for research in 2Q 2022 with the aim to conduct clinical studies in 2023.
Finally, Revive said it will kick off clinical research shortly on its novel psychedelic-assisted therapies, including its tannin-chitosan delivery system, in Antigua and Barbuda, where it is aiming to commercialize products this year in the country.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/971353/revive-therapeutics-updates-on-several-psilocybin-initiatives-to-be-completed-in-2022-971353.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
